Skip to main content Help with accessibility Skip to main navigation

Brolucizumab

Indication

Treating diabetic macular oedema - NICE TA820

NICE TA820 - Brolucizumab for treating diabetic macular oedema

Red

Brand:

Nice TA:

820

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Eye

Background

1.1 Brolucizumab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if:

  • the eye has a central retinal thickness of 400 micrometres or more at the start of treatment

  • the company provides brolucizumab according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 14 - Sep - 2022